Table 2.

Efficacy results of bevacizumab trials [28]

Trial	Line in therapy	Trial years	Number patients enrolled	Comparison	Progression-free survival		Overall survival
					Median difference (months)	Hazard Ratio (95 % confidence interval, P value)	Median difference (months)	Hazard Ratio (95 % confidence interval, P value)
AVF2119g trial [63]	Second line (previously treated with anthracycline and taxane)	2000–2002	462	Bevacizumab plus capecitabine versus capecitabine	0.7	0.98 (0.77–1.25, P < 0.86)	0.6	1.05 (0.86–1.30, P < 0.63)
E2100 trial [4, 10]	First line	2001–2004	722	Bevacizumab plus paclitaxel versus paclitaxel	5.5	0.48 (0.39–0.61, P < 0.0001)	1.7	0.87 (0.72–1.05, P = 0.137)
AVADO trial (BO17708) [13, 28]	First line	2006–2007	736	Bevacizumab plus docetaxel versus docetaxel	0.9	0.62 (0.48–0.79, P = 0.0003)	- 1.7	1.00, 0.76–1.32, P = 0.98)
RIBBON-1 (AVF3694g) [14, 28]	First line	2005–2007	622	Bevacizumab plus taxane/anthracycline versus taxane/anthracycline	1.2	0.64 (0.52–0.80, P < 0.0001)	Not reported	1.11 (0.86–1.43, P = 0.44)
		2005–2007	615	Bevacizumab plus capecitabine versus capecitabine	2.9	0.69 (0.56–0.84, P =0.0002)	2.9	0.88 (0.69–1.13, P = 0.33)
RIBBON-2 (AVF3693g) [28]	Second line	2006–2008	684	Bevacizumab plus taxanes, capecitabine or gemcitabine versus taxanes, capecitabine or gemcitabine	2.1	0.78 (0.64–0.93, P = 0.0072)	Non significant difference